(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
5 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 8.21%
Live Chart Being Loaded With Signals
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology...
Stats | |
---|---|
今日成交量 | 2.47M |
平均成交量 | 1.33M |
市值 | 51.47M |
EPS | $0 ( 2024-03-18 ) |
下一个收益日期 | ( $-0.250 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.530 |
ATR14 | $0.00500 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Grant Stuart M. | Buy | 100 000 | Common stock, par value $0.0001 |
2024-03-19 | Grant Stuart M. | Buy | 50 000 | Common stock, par value $0.0001 |
2024-03-08 | Grant Stuart M. | Buy | 10 717 | Common stock, par value $0.0001 |
2024-02-12 | Gandolfo John P | Buy | 60 000 | Stock Option (right to buy) |
2024-02-12 | Rowe Michael M | Buy | 75 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
68.92 |
Last 95 transactions |
Buy: 2 919 948 | Sell: 334 000 |
音量 相关性
Eyenovia Inc 相关性 - 货币/商品
Eyenovia Inc 财务报表
Annual | 2023 |
营收: | $3 787.00 |
毛利润: | $-783 208 (-20 681.49 %) |
EPS: | $-0.660 |
FY | 2023 |
营收: | $3 787.00 |
毛利润: | $-783 208 (-20 681.49 %) |
EPS: | $-0.660 |
FY | 2022 |
营收: | $0 |
毛利润: | $-307 430 (0.00 %) |
EPS: | $-0.820 |
FY | 2021 |
营收: | $14.00M |
毛利润: | $12.40M (88.57 %) |
EPS: | $-0.607 |
Financial Reports:
No articles found.
Eyenovia Inc
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。